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Abstract
Background MDMA has been shown to induce feelings of
sociability, a positive emotional bias and enhanced empathy.
While previous research has used only visual emotional stim-
uli, communication entails more than that single dimension
and it is known that auditory information is also crucial in this
process. In addition, it is, however, unclear what the neurobi-
ological mechanism underlying these MDMA effects on so-
cial behaviour is. Previously, studies have shown that
MDMA-induced emotional excitability and positive mood
are linked to the action on the serotonin (5-HT) 2A receptor.
Aim The present study aimed at investigating the effect of
MDMA on processing of sounds (Processing of Affective
Sounds Task (PAST)) and cognitive biases (Approach-
Avoidance Task (AAT)) towards emotional and social stimuli
and the role of 5-HT2A receptor in these effects.
Methods Twenty healthy recreational users entered a 2 × 2, pla-
cebo-controlled, within-subject study with ketanserin (40 mg) as
pre-treatment and MDMA (75 mg) as treatment. Behavioural
(PAST, AAT) measures were conducted 90 min after treatment
with MDMA, respectively, 120 min after ketanserin. Self-report
mood measures and oxytocin concentrations were taken at base-
line and before and after behavioural tests.
Results Findings showed that MDMA reduced arousal elicited
by negative sounds. This effect was counteracted by ketanserin
pre-treatment, indicating involvement of the 5-HT2 receptor in
this process. MDMA did not seem to induce a bias towards
emotional and social stimuli. It increased positive and negative
mood ratings and elevated oxytocin plasma concentrations.
The reduction in arousal levels when listening to negative
sounds was not related to the elevated subjective arousal.
Conclusion It is suggested that this decrease in arousal to
negative stimuli reflects potentially a lowering of defences, a
process that might play a role in the therapeutic process.
Keywords MDMA . 5-HT2A receptor . Ketanserin . Sound
processing . Cognitive bias . Oxytocin . Arousal
Introduction
In recent years, a number of experimental studies have con-
sistently shown that single doses ofMDMA (e.g., 75–125mg)
cause an increase in emotional empathy (e.g., (Schmid et al.
2014; Hysek et al. 2014; Kuypers et al. 2014)). Empathy is
only one aspect of social behaviour, and tests are in general
based on visual stimuli, e.g., including the Reading the Mind
in the Eyes test, the Facial Emotion Recognition Task and the
Multifaceted Empathy Test. However, social interactions
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entail more than one sensory dimension, i.e., the auditory
component also plays an important role in this process
(Musson-Moyer 2012; Niedenthal 2007). Since all previous
experimental MDMA studies have used visual stimuli, the
effect of MDMA on the processing of auditory stimuli is not
known. The present study therefore included a paradigm
assessing the cognitive aspect of auditory stimulus recognition
(‘which sound do you hear?’) and the emotional aspects
linked to sound processing, i.e., sound-induced arousal and
self-concern (‘how does this make you feel?’).
Previously, it has been shown that MDMA decreases
amygdala activity and consequently might cause a reduction
in avoidance behaviour (Gamma et al. 2000; Johansen and
Krebs 2009; Bedi et al. 2009). In addition, it has been sug-
gested that MDMA induces a positive emotional bias since
participants rated favourite memories as significantly more
vivid, emotionally intense and positive during MDMA intox-
ication and worst memories as less negative, compared to
placebo (Carhart-Harris et al. 2014). The induction of such a
cognitive bias and the reduction in avoidance behaviour by
MDMAwould explain why MDMA increases sociability and
empathy. A task often used to study cognitive bias is bymeans
of an approach-avoidance task. This paradigm is based on
research indicating that flexions and extensions of the arm
when using a joystick are, respectively, related to implicit
positive evaluation (approach) and negative evaluation
(avoidance) (Neumann and Fritz 2000).
Serotonin (5-HT) and oxytocin systems are known to be
involved in approach-avoidance behaviour; i.e., it was shown
previously that intranasal administered oxytocin regulates 5-
HT1A receptors and thereby interferes with 5-HT transmis-
sion, at the root of the 5-HT system, in the dorsal raphe nucle-
us (Cools et al. 2008). Domes and colleagues showed that
intranasal application of oxytocin led to a valence-
independent modulation of the approach bias and a reduction
of amygdala activity to positive and negative stimuli (Domes
et al. 2007). MDMA has previously been shown to induce an
elevation in peripheral oxytocin concentrations (Kuypers et al.
2014; Dumont et al. 2009), and this might be a mechanism by
which cognitive biases are induced by MDMA. In the present
study, we were interested to test whether MDMA induces a
bias towards emotional and social stimuli and whether this
correlates with oxytocin concentrations.
Pre-clinical evidence showed that changes in the 5-HT2A
receptor responsivity after repeated administration of MDMA
were accompanied by decreased social behaviour suggesting a
role for this receptor in MDMA-induced sociality (Bull et al.
2004). Studies in humans have shown that the 5-HT2A/C plays
an important role in emotion and mood. Liechti and col-
leagues demonstrated that by blocking the 5-HT2A receptor
with ketanserin (50 mg), MDMA (1.5 mg/kg p.o.)-induced
emotional excitation was attenuated (Liechti et al. 2000). In
addition, van Wel and colleagues showed that the effects of a
single dose of MDMA (75 mg) on positive mood were
blocked by pre-treatment with ketanserin (50 mg) while this
was not observed for negative mood effects (van Wel et al.
2012). Since mood and emotional excitability both play a role
in the empathic response and social behaviour, and are linked
with the activation of the 5-HT2A receptor, it was hypothesised
that blockade of this receptor could prevent or even counteract
MDMA-induced behavioural responses to emotional stimuli.
The present study was set up to assess the effects of a single
dose of MDMA (75 mg) on processing of emotional sounds,
implicit attitudes towards social and emotional stimuli, mood,
oxytocin responses and the role of the 5-HT2A receptor herein.
Materials and methods
Participants
Participants were 20 healthy poly-drug MDMA users (12
males), with a mean (SD) age of 21.2 (2.6) years. They had
previous experience with ecstasy/MDMA use and other drugs
(Table 1). They were recruited through advertisements in univer-
sity buildings and a website (digi-prik.nl) and by word of mouth.
Design and treatments
The study was conducted according to a 2 × 2 double-blind,
placebo-controlled, within-subject design including a pre-
treatment and a treatment. Pre-treatment was a ketanserin cap-
sule (40 mg), or placebo; treatment was an MDMA capsule
(75 mg) or placebo. Capsules were administered orally with
water, and all capsules were identically appearing. Ketanserin
40 mg represents a regular therapeutic dose that blocks about
91% of the 5-HT2 receptors (Brogden and Sorkin 1990;
Sharpley et al. 1994).
A permit for obtaining, storing and administering MDMA
was obtained from the Dutch drug enforcement administra-
tion. Randomization of pre-treatment and treatment condi-
tions was generated by means of a Latin square, with each
subject being assigned to a treatment sequence.
Procedures
Prior to participation, all participants were medically assessed
by a physician, who examined general health (including an
ECG) and took blood and urine samples for standard chemis-
try and haematology. After study inclusion and before actual
test days, participants were familiarized with the procedures,
tests and questionnaires on a training day. They were request-
ed to abstain from any drug use 1 week before the medical
examination until the last test day. Participants were asked not
to use any caffeinated or alcoholic beverages 24 h before
testing and to get a normal night’s sleep as assessed.
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Prior to experimental sessions, at 9 a.m., participants were
screened for drugs of abuse consumption in urine (THC, opi-
ates, cocaine, amphetamines, methamphetamines) and had to
pass a breathalyser ethanol test. Women were given a preg-
nancy test. When tests were negative, participants had break-
fast, filled out a questionnaire to assess their mood state
(Profile of Mood States (POMS)) and a blood sample was
taken to assess baseline oxytocin concentrations. Thereafter,
pre-treatment was administered followed 30min later by treat-
ment. POMS and blood samples were taken 90 min after
treatment and followed by behavioural tests. After the test
battery, i.e., 150 min after treatment and 180 min after pre-
treatment, POMS and blood samples were taken again and the
test day ended. Test days were minimally separated by a 7-day
wash-out period.
The study was performed in accordance with the Helsinki
Declaration of 1975 and its amendments and was approved by
the Medical Ethics Committee of the Academic Hospital of
Maastricht and the University of Maastricht. Participants
signed an informed consent and were paid upon completion
of the testing periods for their participation.
Processing of Affective Sounds Task
The Processing of Affective Sounds Task (PAST) was con-
structed to measure the effect of MDMA on processing affec-
tive sounds. Sixty sounds with each a duration of 6 s (30
positive/pleasant, 30 negative/unpleasant) were selected from
the International Affective Digital Sounds database of
(Bradley and Lang 2000) which contains a set of 111 stan-
dardized, emotionally evocative sounds that cover a wide
range of semantic categories (Stevenson and James 2008).
Previously, in a study of Stevenson and James (Stevenson
and James 2008), participants classified to which extent these
sounds belonged to one of five emotional categories (happy,
sad, fear, disgust, anger) and how aroused the sounds made
them feel. For the purpose of our study, we selected the 30
most positive/pleasant (happy) and 30 most negative/
unpleasant (sad (4), fear (19), anger (1), disgust (6)) non-
verbal sounds. Norm data from the selected sounds showed
that on a nine-point scale, the ‘positive’ sounds were judged as
significantly more pleasant (average rating ± SE [7.1 ± 0.9])
than negative sounds (2.8 ± 1.4) (t29 = 16.1; p < 0.001) and
negative sounds were experienced as more arousing
(6.5 ± 0.2) compared to positive sounds (4.8 ± 0.2)
(t29 = −6.7; p < 0.001).
Sounds were presented subsequently through headphones.
Participants had to type in what they thought they heard (cog-
nitive component, recognition) and subsequently had to cate-
gorize the sound as pleasant (rating from one to three), neutral
(zero) or unpleasant (rating from −1 to −3) and rate how
aroused the perception of this sound made them (scale from
one to nine) (emotional component). Only ‘arousal’ and ‘feel-
ing’ ratings from correctly identified sounds were averaged to
yield a mean Arousal or Feeling rating.
Implicit attitude tests
Three versions of the Approach-Avoidance Task (AAT) were
used to test automatic action tendency towards presented stim-
uli (pictures). These included AATs to measure approach-
avoidance behaviour to social, threat and trust stimuli.
Participants were instructed to push or pull a joystick as fast
as possible upon appearance of the stimuli, according to the
rules, independently of the content of the stimulus. They had
to push when the pictures were tilted to the right respectively
to the left and pull when the pictures were tilted 3% to the left
respectively to the right. Upon movement of the joystick, the
picture changed in size such that it grew upon pulling and
shrank upon pushing, creating the visual impression that the
picture itself is being pulled closer (approach) or pushed away
(avoidance). After participants moved the joystick and the
picture changed format, the picture disappeared, irrespective
of whether it was a correct response. Each image was present-
ed four times, i.e., twice in pull and twice in push format. The
resulting trials were presented in a semi-random order, i.e., at
most three similar rotations and image categories in a row and
preceded by 15 practice trials with grey rectangles (procedure
cfr. (Cousijn et al. 2011)). The dependent variable was a bias
score which was calculated by subtracting median approach
reaction time (RT) from median avoid RT for each image
category. The bias could either be positive (approach bias)
Table 1 Self-reported lifetime
history of drug use Drug use (number of times
used in lifetime)
Min Max Mean (SD) N never used Number
Ecstasy/MDMA 3 100 16.8 (23.2) 0 20
Amphetamine 1 3 2.2 (1.0) 16 4
Cannabis 1 300 54.2 (76.2) 2 18a
Cocaine 2 20 7.4 (6.4) 12 8
Mushrooms 1 50 8.6 (18.3) 13 7
LSD 20 20 20.0 (0.0) 19 1
aOne participant answered: ‘I have used this so often, I cannot estimate how often I have used it’
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or be negative (avoidance bias) indicating the automatic action
tendency towards or away from a scene (Social AAT) or an
emotion (Threat AAT/Trust). Before this bias was calculated,
data were corrected for outliers meaning that extreme high
(>2000 ms or ≥3 SD above the individual participants’ mean
RT) or extreme low reaction times (<200 ms or ≤3 SD from
the individual participants’ mean RT) were removed (proce-
dure cf. (Cousijn et al. 2011)).
For both the Threat AAT and the Trust AAT, 24 pictures
(12 neutral + 12 high threat; 12 neutral + 12 high trustwor-
thy) were selected from the data set of Oosterhof and
Todorov (Oosterhof and Todorov 2008). This resulted for
both tasks in 96 trials. For the Social AAT, 36 black and
white pictures were selected containing either nature scenes
(neutral category) or scenes with one (‘social low’) or mul-
tiple persons (‘social high’). Twelve pictures per category
resulted in 144 trials.
The Profile of Mood States
The POMS (de Wit et al. 2002) is a self-assessment mood
questionnaire with 72 five-point Likert scale items,
representing eight mood states; i.e., Anxiety, Depression,
Anger, Vigour, Fatigue, Confusion, Friendliness and Elation.
Two extra scales are derived, i.e., Arousal ((Anxiety + Vigour)
− (Fatigue + Confusion)) and Positive mood (Elation −
Depression). The participant had to indicate to what extent
these items were representing his/her mood.
Pharmacokinetics and oxytocin concentrations
Blood samples were collected three times on each test day in
order to determine oxytocin concentrations and pharmacoki-
netics of MDMA, MDA and ketanserin.
Pharmacokinetics
Samples were centrifuged immediately, and resulting plas-
ma was stored at −20 °C until analysis. MDMA were
determined by gas chromatography coupled to mass spec-
trometry using a method previously described by Pizarro
and colleagues (Pizarro et al. 2002). Ketanserin was de-
termined by liquid chromatography coupled to mass spec-
trometry. Samples (200 μL of plasma) were purified with
Ostro Pass-through Sample Preparation Plates (Waters,
MA, USA) and 600 μL of acetonitrile with 0.1% formic
acid were used as the elution solvent. After mixing, vac-
uum was applied and the collected mixture was evaporat-
ed to dryness at 15 psi and 40 °C. Extract was
reconstituted with 100 μL of ammonium formate 0.02%
at pH 5 and acetonitrile (50:50 v/v). Quantification was
performed in an HPLC system coupled to a triple-
quadrupole (6410 Triple Quad LC-MS; Agilent) mass
spectrometer with an electrospray interface. The chro-
matographic separation was done using a C18 column
(Kinetex, 100 mm × 3 mm × 1.7 μm, Phenomenex, CA,
USA). The mobile phase was ammonium formate 0.02%
at pH 5 and acetonitrile in an isocratic mode (50:50 v/v) at
a flow rate of 0.45 mL/min. All compounds were moni-
tored in positive ionization using the multiple reaction
mode mass/charge (M + 1/z) values selected for identifi-
cation of analytes were as follows: ketanserin 396 → 146,
189, 208; and pirenperone 394 → 119, 159, 187,
fragmentor (F) 200 V, collision energy (CE).
Oxytocin concentrations
A 2-mL sample for oxytocin analysis was drawn and collected
in non-heparinized tubes. Samples were centrifuged at
3500 rpm for 10 min and at 4 °C. Serum was removed and
frozen at −80 °C until analysis. Serum oxytocin concentra-
tions were determined by a fluorescent immunoassay kit
(Phoenix Pharm. Inc., Burlingame, CA) following the manu-
facturers’ instructions, briefly a first extraction step using C18
columns was performed, followed by a fluorimetric EIA anal-
ysis as per protocol.
Statistical analyses
Data entered a general linear model (GLM) repeated mea-
sures analysis of variance (RM ANOVA) procedure
(SPSS, version 24.0) with Pre-treatment (two levels:
ketanserin, placebo) and Treatment (two levels: MDMA,
placebo) as main within-subject factors. Extra within-
subject factors were included for the PAST (Valence,
two levels) and the AATs (Stimulus category, two levels
(Trust, Threat), or three levels (Social)). In case of inter-
action effects, paired t tests were conducted to test the
origin of the interaction.
For the POMS and oxytocin concentrations, threemeasures
were collected including baseline. First, a GLM RMANOVA
was conducted, including only baseline to test for baseline
differences. In case there were no differences, another GLM
was conducted, including only the second or third measure to
test for main and interaction effects of Pre-treatment and
Treatment.
To study whether ketanserin and MDMA plasma concen-
trations differed significantly between conditions in which
ketanserin or MDMAwas administered alone or in combina-
tion, paired sample t tests were conducted.
The alpha criterion level of statistical significance for all
analyses was set at p = 0.05; effect sizes are reported as partial
eta-squared (ƞp2) (magnitude: small = 0.01, moderate = 0.06,
large = 0.14).
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Results
Processing of Affective Sounds Task
Analyses revealed a main effect of Valence on ratings of
Feeling (F1, 19 = 154.31; p < 0.001, ƞp2 = 0.89) and Arousal
(F1, 19 = 22.30; p < 0.001, ƞp2 = 0.54). Positive sounds were
rated as more positive compared to negative sounds, and neg-
ative sounds produced more arousal compared to positive
sounds. Furthermore, there was a three-way interaction of
Pre-treatment × Treatment × Valence (F1, 19 = 8.80;
p = 0.008, ƞp2 = 0.32) on Arousal. When under influence of
MDMA alone, participants were equally aroused by positive
and negative sounds in contrast to the placebo (t19 = −2.59;
p = 0.02) and the combined ketanserin-MDMA condition
(t19 = −2.66; p = 0.02) where participants were more aroused
by negative stimuli. This behavioural pattern in the MDMA
only condition could not be attributed to an increase in rating
of the positive sounds compared to placebo as shown by in-
significant ad hoc t test (t29 = 1.3; p = 0.2). WhenMDMAwas
combined with ketanserin, the MDMA-induced ‘indifference’
with regard to the valence of the sound disappeared and a
differentiation between arousal ratings for positive and nega-
tive sounds was observed, i.e., arousal for negative sounds
was higher than arousal experienced when hearing positive
sounds. This pattern resembled placebo ratings (Fig. 1a).
Otherwise, no main effect of Pre-treatment, Treatment or
their interaction on dependent variables of the PAST was
found (Table 2).
Implicit attitude tests
Threat AAT
Analyses revealed no main effect of Pre-treatment or
Treatment on Threat Bias. The interaction between Pre-
treatment and Treatment approached significance (F1,
19 = 4.13, p = 0.056, ƞp2 = 0.18). Data suggested that treatment
with ketanserin alone increased the approach tendency to-
wards faces, irrespective of the emotional expression com-
pared to placebo; whereas the combination of ketanserin with
MDMA or MDMA alone resulted in an avoidance bias that
was close to zero (Fig. 1b). There was no main effect of
Stimulus category on Threat Bias, i.e., while Threat neutral
faces were approached (6.81) and Threat-High faces were
avoided (−3.25), biases did not statistically significant differ.
Trust AAT
Analysis revealed a Pre-treatment by Treatment interaction
(F1, 19 = 5.17, p = 0.03, ƞp2 = 0.21); additional analyses
showed that this interaction was due to significant differences
between the ketanserin and the placebo condition (t19 = 2.85;
p = 0.01) and ketanserin and the combined condition
(t19 = 2.21; p = 0.04). During placebo, participants displayed
an avoidance bias (−13.5), independent of (emotional) stimu-
lus content; ketanserin alone led to an approach bias. Under
influence of MDMA, the (approach) bias was close to zero
(i.e., 0.7). When ketanserin was combined withMDMA, there
was an avoidance bias (−7.4), which was comparable to pla-
cebo (−13.46). It therefore seems that when combined with
MDMA, the ketanserin’s approaching effects are eliminated
and even reversed. Analyses revealed no main effect of Pre-
treatment or Treatment. There was no main effect of the
Stimulus category, i.e., while Trustworthiness-neutral faces
were approached (bias 5.4) and Trustworthiness-high faces
were avoided (bias −6.4), they did not statistically significant
differ (Fig. 1c).
Social AAT
Analyses revealed a main effect of Pre-treatment on Social
bias (F1, 19 = 4.62, p = 0.04, ƞp2 = 0.20); i.e., under influence
of ketanserin, participants had an avoidance bias (−9.6), irre-
spective of stimulus content, compared to the placebo condi-
tions (9.7). The Pre-treatment by Treatment interaction
approached significance (F1, 19 = 4.16, p = 0.056,
ƞp2 = 0.18) suggesting that when ketanserin (approach bias
3.9) and MDMA (approach bias 16) were combined, this led
to an avoidance bias (−23.1; t19 = 2.4; p = 0.03), indicating a
negative synergy. There was no main effect of the Stimulus
category; the bias for pictures with single and multiple people
(approach biases 2.8 and 4.3) did not differ significantly from
the bias for natural scenes (avoidance bias −6.9) (Fig. 1d).
Profile of Mood States
There were no baseline differences in POMS scores over the
four test days. Analysis including the second (pre-test) mea-
surement revealed main effects of Pre-treatment and
Treatment on 7 out of 10 scales of the POMS. The effects of
ketanserin and MDMA were in opposing directions on
Vigour, Elation, Arousal, Positive Mood and Fatigue. While
ketanserin increased fatigue, MDMA caused a decrease; in
contrast, ketanserin decreased vigour, elation, arousal and pos-
itive mood, while MDMA increases these subjective feelings.
Effects on Anxiety and Confusion were the same for
ketanserin and MDMA; both seemed to increase ratings.
Analysis including the third (post-test) measurement yielded
approximately the same results with the exception of one dif-
ference and four additional effects. The effect of ketanserin on
Anxiety was in the opposite direction compared to the second
measurement, i.e., ketanserin caused a decrease in Anxiety.
During the third measurement, there were two additional main
effects of Pre-treatment and Treatment on Friendliness; i.e.,
ketanserin reduced friendliness, while MDMA increased
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friendliness. Three additional interaction effects were revealed
on Anxiety, Elation and Arousal. When ketanserin was com-
bined with MDMA, effects of MDMAwere counteracted and
ratings were placebo like, i.e., anxiety, elation and arousal
were reduced compared to the MDMA only condition
(Table 3).
Drug pharmacokinetics and oxytocin concentrations
Pharmacokinetics
Paired sample t tests showed that MDMA plasma concen-
trations (ng/mL) did not statistically differ between the
MDMA alone condition (mean (±SE): 90′ post-MDMA:
134.8 (16.6); 150′ post-MDMA: 186.0 (17.7)) and the
condition where it was combined with ketanserin (mean
(±SE): 90′ post-MDMA: 126.7 (15.1); 150′ post-MDMA:
182.9 (14.7)). The same was shown for ketanserin plasma
concentrations (ng/mL), i.e., they did not differ between
the ketanserin alone condition (mean (±SE): 90′ post-
MDMA: 54.9 (7.6); 150′ post-MDMA: 64.5 (6.0)) and
the condition where it was combined with MDMA (mean
(±SE): 90′ post-MDMA: 59.0 (8.8); 150′ post-MDMA:
61.5 (5.4)).
Oxytocin concentrations
Analyses revealed no baseline differences in oxytocin serum
concentrations between treatment conditions. There was a
main effect of MDMA (F1, 13 = 5.71; p = 0.03, ƞp2 = 0.30)
Fig. 1 Mean (±SE) arousal rating
of positive and negative sounds in
the Processing of Affective
Sounds Task in (a), and mean
(±SE) approach-avoidance biases
of threat stimuli (b), trustworthy
stimuli (c) and social stimuli (d)
Table 2 Mean (±SE) and GLMRMmain effects of Valence (V), Pretreatment (PT) and Treatment (T) on Feeling and Arousal during negative (−) and
positive (+) sounds in the Processing Auditory Stimuli Task (PAST); p = – depicts statistical insignificance at p < 0.05
Mean (±SE) ratings Main effects RM GLM ANOVA
PT PLA PLA KET KET V PT T
T PLA MDMA PLA MDMA F1, 19 p F1, 19 p F1, 19 p
Feeling + 1.0 (0.1) 1.2 (0.1) 1.1 (0.1) 1.3 (0.1) 154.31 <0.001 0.34 – 1.49 –
Feeling − −0.9 (0.1) −0.8 (0.1) −0.9 (0.1) −0.9 (0.1)
Arousal + 3.8 (0.4) 4.0 (0.4) 4.1 (0.3) 3.8 (0.3) 22.30 <0.001 0.21 – 0.43 –
Arousal − 4.9 (0.4) 4.7 (0.4) 5.0 (0.4) 5.0 (0.4)
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on oxytocin concentrations 90 min after administration, i.e.,
MDMA caused an increase in oxytocin concentrations
(0.8 ± 0.1 pg/mL) compared to placebo (0.5 ± 0.1 pg/mL).
There was no main effect of Pre-treatment or a Pre-treatment
by Treatment interaction on oxytocin concentrations, 90′ after
MDMA treatment.
Analyses revealed a main effect of Pre-treatment (F1,
11 = 16.90; p = 0.002, ƞp2 = 0.61) and a Pre-treatment by
Treatment interaction effect (F1, 11 = 5.29; p = 0.04,
ƞp2 = 0.32) on oxytocin concentrations, 150′ after
MDMA administration. The main effect demonstrated a
decrease in oxytocin concentrations after ketanserin
treatment (0.3 ± 0.1 pg/mL) compared to placebo
(0.8 ± 0.2 pg/mL). The interaction effect showed that
ketanserin blocked the MDMA-induced elevation in oxy-
tocin concentrations.
Post hoc correlations
Seen the effects of MDMA on Arousal in the PAST, cor-
relations between this parameter and Arousal and Anxiety
of the POMS and oxytocin concentrations were calculated
in order to explore the relation between general levels of
anxiety and arousal, oxytocin levels and task-related
Table 3 Mean (±SE) and GLM outcomes of dependent variables of the POMS; 1 = POMS baseline measurement, 2 = POMS measurement before
cognitive tests (peak drug) and 3 = POMS measurement after cognitive tests (end of test day); p = – depicts statistical insignificance at p < 0.05
Mood scales Mean (±SE) mood scales Main and interaction effect GLM RM ANOVA
PT PLA PLA KET KET PT T PT × T
T PLA MDMA PLA MDMA F1, 19 p F1, 19 p F1, 19 p
Anxiety 1 2.7 (0.3) 2.8 (0.3) 2.5 (0.3) 3.0 (0.5) 0.94 – 0.36 – 0.50 –
2 2.0 (0.3) 4.8 (0.9) 2.4 (0.3) 4.7 (0.6) 0.08 0.00 32.42 0.00 0.21 –
3 2.5 (0.2) 5.8 (0.7) 3.0 (0.3) 3.2 (0.4) 9.73 0.00 18.62 0.00 13.73 0.001
Depression 1 0.1 (0.1) 0.2 (0.1) 0.2 (0.2) 0.4 (0.3) 0.65 – 0.43 – 0.07 –
2 0.2 (0.2) 0.1 (0.1) 0.4 (0.2) 0.6 (0.3) 2.58 – 0.00 – 0.61 –
3 0.4 (0.1) 0.5 (0.2) 0.5 (0.2) 0.2 (0.1) 0.15 – 0.18 – 1.75 –
Anger 1 0.7 (0.2) 0.8 (0.2) 1.2 (0.3) 0.9 (0.3) 2.65 – 0.12 – 0.56 –
2 0.8 (0.3) 0.9 (0.2) 0.5 (0.2) 0.8 (0.3) 0.96 – 2.49 – 0.80 –
3 0.9 (0.3) 1.2 (0.3) 0.6 (0.0) 0.4 (0.2) 8.89 – 0.18 – 1.77 –
Vigour 1 11.2 (1.1) 12.2 (1.2) 11.9 (1.3) 11.7 (1.1) 0.04 – 0.41 – 0.80 –
2 10.0 (1.2) 13.7 (1.3) 6.5 (1.1) 11.4 (1.7) 9.09 0.001 16.72 0.001 0.41 –
3 9.4 (1.2) 13.8 (1.4) 6.10 (0.8) 9.0 (1.4) 34.10 0.00 18.54 0.00 2.37 –
Fatigue 1 1.3 (0.5) 1.4 (0.4) 1.4 (0.4) 1.9 (0.6) 0.85 – 0.64 – 0.29 –
2 2.1 (0.6) 1.0 (0.3) 6.7 (1.4) 4.5 (1.5) 10.69 0.03 5.73 0.03 0.44 –
3 4.3 (1.3) 1.7 (1.2) 7.4 (1.5) 5.3 (1.2) 18.27 0.04 4.79 0.04 0.10 –
Confusion 1 3.1 (0.2) 3.6 (0.4) 3.3 (0.3) 3.4 (0.6) 0.01 – 0.89 – 0.36 –
2 3.7 (0.33) 4.7 (0.5) 5.1 (0.5) 7.2 (0.9) 9.51 0.01 7.43 0.01 1.92 –
3 4.7 (0.6) 6.4 (0.6) 6.1 (0.4) 7.6 (0.9) 17.51 0.03 5.87 0.03 0.05 –
Friendliness 1 16.8 (1.2) 17.5 (1.4) 17.3 (1.6) 18.0 (1.2) 0.56 – 0.82 – 0.00 –
2 15.9 (1.4) 16.7 (1.8) 14.6 (1.4) 16.6 (1.5) 0.66 – 2.93 – 0.73 –
3 15.2 (1.4) 18.4 (1.5) 13.4 (1.6) 15.9 (1.5) 7.66 0.006 9.58 0.006 0.18 –
Elation 1 10.4 (0.8) 11.2 (0.8) 10.9 (1.0) 11.5 (0.8) 0.86 – 2.02 – 0.04 –
2 10.0 (1.0) 12.6 (1.1) 8.4 (0.7) 11.3 (1.3) 4.19 0.005 9.92 0.005 0.06 –
3 8.6 (0.9) 13.3 (1.0) 7.4 (1.0) 10.2 (1.0) 12.26 0.000 25.28 0.00 4.87 0.04
Arousal 1 9.5 (1.5) 10.0 (1.4) 9.6 (1.6) 9.4 (1.6) 0.05 – 0.02 – 0.13 –
2 6.1 (1.5) 12.8 (1.8) −2.8 (2.2) 4.3 (3.5) 9.30 0.001 14.30 0.001 0.01 –
3 3.0 (2.3) 11.5 (2.5) −4.4 (1.9) −0.8 (2.6) 39.07 0.004 10.98 0.004 6.49 0.02
Positive mood 1 10.3 (0.9) 11.0 (0.9) 10.7 (1.0) 11.1 (1.0) 0.28 – 0.79 – 0.07 –
2 9.7 (1.0) 12.5 (1.1) 8.0 (0.8) 10.7 (1.4) 4.49 0.007 8.97 0.007 0.00 –
3 8.2 (1.0) 12.8 (1.0) 6.9 (1.0) 9.9 (1.0) 7.55 0.00 23.91 0.00 3.37 –
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arousal. The correlations (r20) were not statistically signif-
icant and ranged between −0.2 and 0.2 for POMS arousal-
PAST arousal, −0.1 and 0.3 for POMS anxiety-PAST
arousal and −0.3 and 0.3 for oxytocin concentrations-
PAST arousal.
In addition, since oxytocin is involved in social behaviour
and ketanserin blocked the effects of MDMA on oxytocin
concentrations, and three POMS scales, i.e., Anxiety, Elation
and Arousal, correlations were calculated to test whether
POMS and oxytocin concentrations were associated.
Pearson’s correlations were not statistically significant for
the three scales, i.e., r20 = 0.3 for POMS anxiety, r20 = 0.4
for POMS arousal and r20 = −0.1 for POMS elation.
Discussion
The aim of the present study was to investigate the effect of
MDMA (75 mg) on processing of auditory stimuli; implicit
attitudes towards social and emotional stimuli, mood and oxy-
tocin concentrations and the role of the 5-HT2A receptor in
these effects. It was demonstrated that MDMA reduced arous-
al experienced by negative sounds. This effect was
counteracted by ketanserin. Findings showed in general no
effects of MDMA on approach-avoidance behaviour.
Ketanserin, however, induced avoidance behaviour in the
Social AAT, independent of stimulus content, and approach
behaviour in the Trust AAT, when it was administered alone.
When combined with MDMA, approach behaviour in the
Trust AATwas decreased. MDMA caused, in line with previ-
ous findings (Kuypers et al. 2014; van Wel et al. 2012), an
increase in positive and negative mood, it lowered ratings of
fatigue and it increased oxytocin plasma concentrations.
Ketanserin counteracted a selection of MDMA-induced mood
effects 150 min after MDMA intake.
In the Processing of Affective Sounds task, it was shown
thatMDMA reduced arousal induced by negative sounds; pre-
treatment with ketanserin changed the MDMA response, i.e.,
increasing the arousal experienced by negative sounds and
thereby returning the arousal levels to a placebo-like response.
This placebo response was in line with the norm data onwhich
the task was based (Stevenson and James 2008) and previous
findings in non-drug using volunteers, showing that listening
to unpleasant sounds induced larger startle reflexes and larger
heart rate decelerations compared with listening to pleasant
sounds. It was suggested that these sounds activated the appe-
titive and defensive motivational circuits (Bradley and Lang
2000). Our findings suggest an MDMA-induced indifference
to negative sounds, or an inhibition of fear induced by nega-
tive sounds, which could hint at an inhibition of in-built fear
responses (Phillips et al. 1998). These findings are also in line
with a rodent study, showing disruption of pre-pulse inhibition
after treatment with MDMA, which was counteracted by a
selective 5-HT2A receptor antagonist. It was concluded that
the effect of MDMA was caused by action on this receptor
(Padich et al. 1996).
The absence of significant correlations between self-rated
arousal levels on the POMS in the separate drug conditions
and the arousal elicited by the emotional sounds demonstrates
that the observed effects were not simply related to a general
MDMA effect on arousal levels but were stimulus dependent.
While the general level of arousal was rated higher in the
MDMA condition and lower when MDMA was combined
with ketanserin, this pattern was opposite when confronted
with auditory stimuli in the PAST. So, during MDMA intox-
ication participants experienced more general arousal but
stimulus-related arousal was less, especially when confronted
with negative stimuli. This is a very interesting reaction, and it
can be suggested that participants felt less discomfort or more
at ease when they heard negative sounds. This could contrib-
ute to the therapeutic potential of MDMA in a therapeutic
setting, i.e., when patients are asked to talk about their nega-
tive experiences and then being confronted in an auditory way
with the negative wording, their arousal levels might, not in-
crease, their defences might be lowered which has been sug-
gested to contribute to the therapeutic process (Greer and
Tolbert 1990).
MDMA induced in general no cognitive bias, as suggested
by the absence of effects on the approach-avoidance tasks. In
the Trust-AAT, it counterintuitively decreased the ketanserin-
induced stimulus-intensity-independent approach behaviour.
Interestingly, many studies have shown that approach and
avoidance arm movements are facilitated by positive and neg-
ative affect, respectively (Phaf et al. 2014). MDMA is known
to cause an increase in both affective states (van Wel et al.
2012), e.g., increasing positive mood but in parallel also ele-
vating feelings of anxiety and confusion. This effect on both
mood states could explain the lack of hypothesised effects.
Separately blocking the positive and negative mood effects
of MDMA could be used to test whether MDMA induces a
mood-congruent cognitive bias, i.e., approaching when in a
positive mood and avoiding when in a negative mood state.
Previously, it was shown that negative mood effects (anxiety)
could be blocked by using verbal support during an MDMA
session (Vizeli and Liechti 2017), while positive effects were
inhibited by using ketanserin in combination with MDMA
(van Wel et al. 2012). In addition, while previous research
demonstrated that intranasal administration of oxytocin mod-
ulates approach bias (Domes et al. 2007), it was shown that
the MDMA-induced increase in oxytocin plasma concentra-
tions is smaller than the increase induced by intranasal admin-
istered oxytocin (Kuypers et al. 2014). The latter potentially
also explains why in the present study, no MDMA-induced
bias was found.
In line with previous studies (Kuypers et al. 2014; Dumont
et al. 2009), MDMA caused an increase in oxytocin
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concentrations, 90 and 150 min after administration, i.e.,
oxytocin plasma concentrations were doubled compared
to placebo. Interestingly, ketanserin blocked this
MDMA-induced elevation in oxytocin concentrations but
only 150 min after MDMA administration, i.e., 180 min
after pre-treatment with ketanserin. This effect was not
observed 90 min after MDMA administration, respective-
ly, 110 min after ketanserin pre-treatment. The ketanserin-
induced changes in oxytocin concentrations were not as-
sociated with the ketanserin-induced changes in MDMA-
mood effects. Ketanserin works as an antagonist on 5-
HT2A and 5-HT2C receptors, and previously, animal stud-
ies have shown that the 5-HT2C receptor is involved in
oxytocin secretion (Jørgensen et al. 2003). It is therefore
suggested that the MDMA-induced elevation of oxytocin
concentrations could be attributed to its action on the 5-
HT2C receptor, though this needs to be investigated fur-
ther. In addition to this, previous research has shown the
oxytocin receptor gene to be associated with sociability
feelings during MDMA intoxication (Bershad et al.
2016) and with the efficiency of social auditory process-
ing (Tops et al. 2011). Together, these findings suggest
that the oxytocin receptor gene in combination with ac-
tions on the 5-HT2C receptor could also mediate the effi-
ciency of sound processing after MDMA administration.
In conclusion, present findings seem to suggest that a
single dose of MDMA (75 mg) does not induce a specific
bias towards emotional or social stimuli but it reduces
arousal experienced by listening to negative sounds. The
latter effect seems to be mediated by the 5-HT2A receptor,
since ketanserin blocked this effect. This behavioural ef-
fect was not related to subjectively experienced arousal. It
is suggested that this seemingly lowering of defences
when confronted with negative stimuli might play a role
in the therapeutic process.
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